CompletedPhase 1

Lantus in Prediabetes

United States20 participantsStarted 2002-02

Plain-language summary

To assess the safety, tolerability, and efficacy of Lantus® (insulin glargine) in prediabetes (IFG or IGT).

Who can participate

Age range18 Years – 70 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Hyperglycemia (either IGT , IFG, or untreated type 2 diabetes) * HbA1c \< 7.0% * BMI \< 40kg/m2 * Able to perform moderate stationary bicycle exercise Exclusion Criteria: * Chronic pharmacologic treatment for hyperglycemia, past or present * CAD * serum creatinine \> 2.0mg/dL * BP \> 180/105 * History of hypoglycemia unawareness

What they're measuring

Efficacy: 8-point blood glucose measurements.

Safety / tolerability: hypoglycemia

Trial details

NCT IDNCT00348972

SponsorSanofi

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

View on ClinicalTrials.gov More Hyperglycemia trials